（週二早7）專訪：台灣生技研發企業家 陳水田

台灣生技業研發實力，世界有目共睹，更成立國家生技研究園區，網羅具有研發新藥潛力的公司，72歲的陳水田博士，就是其中一員。 5年前陳水田從中研院退休後，把退休金作為創業基金，投入新藥開發，為產業孕育人才。 With internationally reputed biotech Research & Development competence, Taiwan established the National Biotechnology Research Park and recruited those with new-drug development capacity and Dr. Shui-Tein Chen is one of them. Retiring from the Academia Sinica five years ago, Dr. Chen began his additional engagements in new-drug development and talent development with his pension as the startup founding. 坐落在南港的國家生技研究園區，是全台首座跨部會整合園區，以新藥研發為主。並配合國家發展生技醫藥產業，特別設立創服育成中心。首批進駐業者，通過嚴格審查，在百名廠商中，脫穎而出。 Located in Nangang District, the National Biotechnology Research Park is Taiwan’s first cross-ministerial integrated park dedicated to new drug development. In coordination with the national policy in developing the biotechnology industry, the BioHub Taiwan was founded. After stringent evaluation, only few companies were selected out of more than 100 applicants in the first run selection. 生技公司董事長 陳水田：「第一個題目是我在中研院申請專利的，一個肺癌的早期的一個生物檢體蛋白質。(第二)小分子藥就是做牛樟芝，那審查委員覺得這2個，符合這個園區進駐的，應該有的條件，而且超過這個條件，所以他第一次就批准我們可以進駐。」 Biotech company chairperson Dr. Chen: “The first subject, “An Early Bioptic Protein of Lung Cancer,” was the patent I applied for when I was at the Academia, and AC fungus is (the second subject) for small molecule drugs. The IRB considered that the two subjects meet and even surpass the qualification of park entry requirements, so they approved our entry application with our first attempt.” 帶領這家生技公司，是72歲的董事長陳水田，台大生化所博士、前中研院生化所研究員暨總務長。陳水田擁有37年的研究基礎，及多項研究成果。技轉給多家上市櫃生技公司，協助台灣生技產業發展。 This biotech company is under the leadership of Dr. Shui-Tein Chen at his age of 72. He earned a PhD in biochemistry from the NTU and has been the former research fellow and general affairs president of Academia Sinica. With 37 years of experience in fundamental research and a wide range of research achievements. He has transferred his achievements to many listed biotech companies to nourish the growth of Taiwan’s biotech industry. 生技公司董事長 陳水田：「我自己覺得說，生技是一個很重要的一個題目。那我自己也是在實驗室腳踏實地做，所以我也很希望，這樣的腳踏實地的精神，跟訓練我們學生的這些精神，可以帶到生技公司。」 Dr. Chen: “In my opinion, biotech is a very important issue and I do research step by step in the lab. I hope that I can bring this down-to-earth spirit and carry the way I train students from labs to the biotech company.” 退休金，成了陳水田的創業基金。在太太的支持下，67歲成立生技公司，專注在天然物及生物化學的相關研究，握有2大核心技術。進一步將牛樟芝萃取技術，投入武漢肺炎的新藥研究。 Dr. Chen’s startup funding came from his retire pension. With the full support from his wife, Dr. Chen at age of 67, established a biotech company specializing in the research which is related to natural substances and biochemistry with two core technologies. Dr. Chen further engages in developing new drugs for COVID-19 with the AC fugus extraction technology. 生技公司董事長 陳水田：「我們把這一個，肺的細胞或是免疫細胞處理，這個牛樟的萃取物，他的ACE2是會降低的，降低到幾乎差不多60%、70%以下。5月底以前我們的動物實驗通通做完。」 Chairman Dr. Chen: “We treat lung cells or immunocytes with AC fungus extracts. The ACE2 of cells has been reduced to almost below 70-60%. All of the animal tests will be completed in May 2021.” 腳踏實地，是陳水田的人生態度。一步一步，完成實驗任務。 Being down to earth is how Dr. Chen sees life. He believes in taking one step at a time to accomplish his goals. 生技公司董事長 陳水田：「雖然我們有這樣好的計畫五年十年，一定是還要有人來傳承願意做，所以我要找到，更好的人願意投入的人來做才有，這個是我想是，目前我這個年齡的人想到的問題，因為我不會想到說，去遊山玩水就出去，把生命放在那個地方，是還有一點點使命。」 Dr. Chen: “No matter how good our plans are, in 5 or 10 years, we are looking for someone who has passion and vision to carry on. So, I need talents who are better and more willing to engage in related research. This is my expectation. Most people at my age, at least not me, would like to travel around and have fun in the rest of their life. For me, I still have a bit of mission to work on.”)) 會有這般感觸，或許跟陳水田的成長經歷有關。家中世代務農，陳水田高中和大學都讀夜間部，總共讀了10年。高中時，陳水田到台大化學系打工。沒想到，因此跟化學結下不解之緣。 Such a remark may have something to do with Dr. Chen’s achievements. Dr. Chen came from a farmer family and spent 10 years to finish his secondary and higher education at the evening school. When he was a high school student, he worked as a part-time